UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS) (PRNewswire) - Sep 9, 2026 - "The designation is supported by preliminary clinical evidence from the IMPACT study..."
Breakthrough therapy • Immunology
|